Traversing the valley of glycemic control despair by Chase, J.G. & Dickson JL
EDITORIAL Open Access
Traversing the valley of glycemic control
despair
J. Geoffrey Chase* and Jennifer L. Dickson
See related research by Mesotten et al. https://ccforum.biomedcentral.com/articles/10.1186/s13054-017-1799-6
Keywords: Glycemic control, Intensive care, Critical care, Repeatable, Clinical trial, Change, Replicable, Quality, LOGIC
The debate on glycemic control (GC) in critical care
nears the 16-year mark since the initial landmark study.
In this journal, Mesotten et al. [1], from the Leuven
group of the original study, present the results of the
LOGIC-2 multicenter trial of model-based GC versus
standard nurse GC.
In 1979 Kelley and Conner [2] published the “Emo-
tional Cycle of Change” defining five emotional phases
involved in any major change: 1) uninformed optimism;
2) informed pessimism; 3) the valley of despair—where
many “opt out”; 4) informed optimism; and eventually 5)
completion and success.
We have certainly seen uninformed optimism at initial
results [3], followed by many unsuccessful attempts to
repeat them and the rise of (increasingly) informed pes-
simism [4–6]. The resulting confusion in the field led to
rival camps of “believers” agreeing to disagree [7], and
the valley of despair as many clinicians found GC un-
necessary [8], despite strong associations between GC
performance, such as time in band and reduced
hypoglycemia, and clinical outcomes [9].
The results of the study by Mesotten et al, in the con-
text of other very recent results, suggest GC has made it
to step 4—informed optimism.
Very recent analysis in this journal suggests the associ-
ation between mortality and glycemic levels, safety, and
variability is a function of the quality of GC and not of
patient condition or outcome, indicating GC can play a
major role in patient outcomes [10]. Other results in the
journal have indicated achieving outcome benefits re-
quires essentially all patients receive safe, effective GC
[11]. Hence, we can begin to conclude that GC is
important, yet very difficult, and thus how it is imple-
mented may matter as much as whether it is
implemented.
In light of these points, the multicenter LOGIC study
[1] offers two key insights into the main needs and the
basis of future success in GC in critical care … thus tak-
ing us to informed optimism.
First is the need for repeatability across patients, best
defined as the need for patient-specific “one method fits
all” solutions, where many studies fail to achieve safe, ef-
fective control for (essentially) all patients [12]. Second,
and most critical, is the need for repeatability across units,
where many prior trials have failed at the hurdle of vari-
able performance within, but especially across, units. The
results by Mesotten et al. in [1] support both these needs.
Repeatability across patients
Humans are horribly variable [13], and perhaps none
more so than glycemically dysregulated critical care pa-
tients. Patient-specific responses to insulin and nutrition
interventions can differ substantially over just a few
hours between measurements [10, 14]. The use of
model-based and model predictive control in [1] pro-
vides tight, safe, and effective performance matching the
well-known and acclaimed nursing control in the Leuven
center.
The key element of the protocol used in the LOGIC
study is the ability to adapt care to changing, patient-
specific condition using advanced modeling and math-
ematics [12]. These models, methods, and associated vir-
tual patients offer opportunities to make care consistent
to patient condition, rather than consistent to measured
patient responses. This subtle difference provides a level
of adaptability and specificity that is not consistently
possible with most, if not all, clinical protocols, where
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Leuven is often the exception proving the rule. The re-
sult is highly replicable control and consistency per-
patient in control across each individual critical care unit
in this study.
Repeatability across units
Hyperglycemic humans, as well as clinical practice and
culture, are also horribly variable across critical care
units. A key failing in many of the larger, multicenter
randomized trials of GC was the inability to get consist-
ent quality control in every unit [4–6]. Thus, patients re-
ceived variable safety and performance in GC, and it
became hard to obtain a significant change in patient
outcomes. Mesotten et al. show very consistent GC
across three different intensive care units, similar tight-
ness to target glycemia (median blood glucose within
4 mg/dL), and similar variability (standard deviation of
9–10 mg/dL) for two of three units.
This level of consistency across units has only been
shown one other time, to the best of the authors’ know-
ledge, with almost identical GC across two units with
very different patient cohorts and clinical practice cul-
tures [15]. This study also used patient-specific, model-
predictive GC, via the STAR protocol. Thus, very close
or identical replicability across intensive care units has
only been achieved with model-based GC protocols—an
indication of the difficulty of achieving replicable GC for
both patients and across units.
Most importantly, the ability to achieve replicable re-
sults across units with different clinical approaches, pa-
tients, and cultures provides much greater confidence
that a large randomized trial would provide the required
quality control to all patients. In the authors’ opinion,
the inability to accomplish this outcome and the confu-
sion engendered by this inability has delayed acceptance
of GC and its potential to improve outcomes far more
so than any other factor.
A strong opinion in closing
In short, this editorial opinion strongly recommends that
any future GC trial be first required to show such replic-
ability of safety, performance, and workload in standard
care before commencement. We would go further and
state that given the need to achieve safe, effective control
for nearly all patients to ensure outcomes might be seen,
the failure to do so would impose significant burden on
patients and clinicians for no potential outcome.
All new protocols, treatments, and technologies in-
volve change. The bigger the change, often the greater
the resistance and difficulty to implement. Thus, as GC
moves, we believe, to informed optimism, the results by
Mesotten et al. and other recent results show that com-
pletion and success is achievable, but only through rep-
licability, across all patients, and across all units.
Our goals now should be to ask what technologies,
models, and other practices will best let us achieve these
goals, and how to disseminate their uptake more
rapidly?
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